Search Results
Your search for all items matches 34003 pages
Showing 751 - 800LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets
The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 15, 2024, tepotinib (Tepmetko)-—a kinase inhibitor directed against MET, including variants with exon 14 skipping—was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping ...
NADINA Trial Shows Robust Benefit for Neoadjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by total lymph node dissection, with adjuvant therapy guided by depth of response, led to a highly...
Pancreatic Surgeon Named New Director of Moores Cancer Center at UC San Diego Health
Following an extensive national search, Diane M. Simeone, MD, has been appointed Director of Moores Cancer Center at the University of California (UC) San Diego Health. Dr. Simeone brings institutional, national, and international leadership experience both to oncologic patient care and scientific...
Cardiotoxicity: How Far Have We Come?
A little more than 12 months ago, the first major cardio-oncology guidelines were published by the European Society of Cardiology (ESC).1 The extensive document embodied the immense progress of this subspecialty over its short existence. In reaching this milestone, it is worth considering what...
Optimizing the Management of DCIS
“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said E. Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor at Duke University, who ...
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemoradiotherapy. These findings of the phase III LAURA trial suggest that osimertinib may become a new...
New Risk Stratification Model for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology, Zanwar et al developed a prognostic model for overall survival in patients with Waldenström’s macroglobulinemia based on age, albumin level, and lactate dehydrogenase (LDH) level. Study Details In the study, data from 889 consecutive treatment-naive...
FDA Approves Imetelstat for Patients With Low- to Intermediate-1 Risk MDS and Transfusion-Dependent Anemia
On June 6, 2024, the U.S. Food and Drug Administration (FDA) approved imetelstat (Rytelo), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks...
Can Pembrolizumab Improve Outcomes in Soft-Tissue Sarcoma?
The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504). Background Soft-tissue sarcoma is a rare type of cancer affecting muscles, fat, and other connective...
Addition of Chemoradiation to Adjuvant Systemic Therapy: Differences in Node-Negative vs Node-Positive Pancreatic Cancer
Researchers have examined whether adding chemoradiation to adjuvant systemic therapy may improve survival outcomes in patients with resected periampullary pancreatic adenocarcinoma, according to recent findings presented by Abrams et al at the 2024 ASCO Annual Meeting (Abstract 4005). Study Methods ...
Study Identifies Subset of Patients With Lung Adenocarcinoma Who Have HER2 Alterations
Researchers have found that about 6% of patients with non–small cell lung cancer (NSCLC) and KRAS, EGFR, or ALK gene mutations may also have HER2 alterations, according to recent findings presented by Dahake et al at the 2024 ASCO Annual Meeting (Abstract 8534). Background Lung adenocarcinoma is...
Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free...
Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT
In a component of the phase III RADICALS-HD trial reported in The Lancet, Chris C. Parker, MD, and colleagues found that metastasis-free survival was not significantly improved with 6 months of androgen-deprivation therapy (ADT) vs no ADT together with adjuvant radiotherapy in patients with...
Childhood Cancer Survivors: Burden of Cardiovascular Disease and Risk of Major Cardiovascular Events
In an analysis from the St. Jude Lifetime Cohort Study (SJLIFE) reported in The Lancet Oncology, Hammoud et al found that survivors of childhood cancer had a greater risk of major adverse cardiovascular events vs matched community controls, and that an increasing burden of nonmajor events increased ...
PROs From the HIMALAYA Trial in Unresectable Hepatocellular Carcinoma
As reported in the Journal of Clinical Oncology by Sangro et al, patient-reported outcome (PRO) analysis in the phase III HIMALAYA trial showed that tremelimumab/durvalumab and durvalumab produced better outcomes than sorafenib in patients with unresectable hepatocellular carcinoma (HCC). The trial ...
Proton Therapy vs Traditional Radiation Therapy in Patients With Oropharyngeal Cancer
Intensity-modulated proton therapy may achieve similar clinical outcomes and offer significant benefits compared with traditional intensity-modulated radiation therapy in patients with oropharyngeal cancer, according to preliminary data from a multi-institutional phase III trial presented by Frank...
Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Neoadjuvant Pembrolizumab May Improve Outcomes in Some Patients With Colorectal Cancer Surgery
Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–high colorectal cancer. Interim findings from the phase II NEOPRISM-CRC clinical trial were presented...
Chemotherapy Administration and Survival in Patients With Very Advanced Solid Tumors
In a study reported in JAMA Oncology, Canavan et al found no differences in overall survival between oncology practices that were more vs less likely to provide chemotherapy within the last 2 weeks of life to patients with very advanced solid tumors. As stated by the investigators, “ASCO and the...
Aspirin as Adjuvant Therapy for Breast Cancer
As reported in JAMA by Wendy Y. Chen, MD, MPH, and colleagues, interim analysis of the phase III Alliance A011502 trial has shown no invasive disease–free survival benefit with adjuvant aspirin vs placebo in patients with high-risk nonmetastatic breast cancer. The trial was suspended early due to...
Dennis J. Slamon, MD, PhD, Awarded 2024 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research (NFCR) announced that the blue-ribbon selection committee, composed of world-renowned research leaders and visionaries, has awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research to Dennis J. Slamon, MD, PhD, of UCLA Health, for his...
New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer
Researchers have shown the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings published by Temel et al in JAMA and simultaneously presented at the 2024 ASCO Annual Meeting (Abstract 12000). Background More intensive...
Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women
High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer compared with White women with the disease, according to new findings presented by Engel et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Background Triple-negative...
Stress Related to Residing in Violent Neighborhoods May Be Tied to Aggressive Lung Cancer in Black Men
Exposure to increased neighborhood violence may change the glucocorticoid receptor for the stress hormone cortisol and influence the aggressiveness of lung cancer, according to new findings presented by Heath et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Study Methods and...
IMRT Reirradiation Plus Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma
In a phase II study reported in JAMA Oncology, Saba et al found that the addition of nivolumab to intensity-modulated radiation therapy (IMRT) reirradiation improved progression-free survival in patients with recurrent or second primary head and neck squamous cell carcinoma. ...
Adjuvant Radiotherapy With 24 vs 6 Months of ADT in Prostate Cancer
In a component of the phase III RADICALS-HD trial reported in The Lancet, Parker et al found that metastasis-free survival was improved with the addition of 24 months vs 6 months of androgen-deprivation therapy (ADT) to adjuvant radiotherapy in prostate cancer. A second component of the trial, not...
Many Breast Cancer Survivors May Experience Excess Weight Gain
Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...
Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma
A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy called huCART19-IL18 may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell therapy, according to recent findings from a phase I clinical trial presented by Svoboda et al at...
Risk Factors and Outcomes Among Women With Interval vs Screen-Detected Breast Cancer
In a Korean study reported in JAMA Network Open, Song et al identified risk factors for interval breast cancer vs screen-detected breast cancer and described mortality outcomes for women in the two categories. Study Details The retrospective cohort study used data from the Korean National Health...
Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).
Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).
Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients...
Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations...
Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use
Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with...
Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients
Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care for...
William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus...
Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study
Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk ...
Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study
Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).
Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach
Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).
Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy
Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).
Narjust Florez, MD, and Suresh S. Ramalingam, MD, on EGFR-Mutated NSCLC: Update on Osimertinib and Chemoradiotherapy
Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation...
Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in ...
Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer...
Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan
Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial...
Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were...
Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal ...
